# Clinical Performance of Synthesized Two-dimensional Mammography Combined with Tomosynthesis in a Large Screening Population

Aujero MP, Gavenonis SC, Benjamin R, Zhang Z, Holt JS – Christiana Care Health System, Newark, DE *Radiology.* 2017 Apr;283(1):70-76. doi: 10.1148/radiol.2017162674. Epub 2017 Feb 21.

## Objective

The purpose of this study was to evaluate and compare the clinical performance of synthesized 2D (s2D) and DBT, FFDM and DBT to and FFDM alone, in a large community based screening population. The group analyzed outcomes performance, including recall rates, positive predictive values, cancer detection rate among others.

Modality	Screening examinations		
Full-Field Digital Mammography (FFDM)	32,076		
Digital Breast Tomosynthesis + FFDM (DBT + FFDM)	30,561		
DBT + s2D (synthesized 2D image)	16,173		
Total	78,810		

### Methods

This was a retrospective study evaluating 78,810 screening exams performed during October 2011 through June 2016

#### Results

Recall rates with DBT-s2D were statistically significantly lower when compared to DBT-FFDM and FFDM alone. DBT-s2D image format, the detection of invasive cancer and positive predictive values were significantly higher compared to DBT-FFDM.

Findings	DBT + s2D	DBT + FFDM	FFDM
Recall rate	4.3%	5.8%	8.7%
Cancer detection rate	6.1/1000	6.4/1000	5.3/1000
Invasive cancer detection rate	76.5%	61.3%	

Positive Predictive Value	DBT + s2D	DBT + FFDM	FFDM
<b>PPV1</b> (number of cancers divided by number of recalls)	14.3%	10.9%	6%
<b>PPV2</b> (number of cancers divided by number of biopsies)	39.3%	26.3%	20.9%
<b>PPV3</b> (number of cancers divided by number of biopsies perform)	40.8%	28.5%	22.2%

### Conclusion

The improvement in recall rates and positive predictive values, without a reduction in cancer detection rate, verifies screening with DBT-s2D mammography in a large community-based practice is acceptable when compared with DBT-FFDM and FFDM alone.

For the patient, DBT + s2D in screening mammography will reduce the radiation exposure compared to the use of DBT + FFDM. False-positive findings are expected to decrease and the number of invasive cancers will be comparable to those found at screening with DBT + FFDM.

Summary presented by Hologic Medical Education

hologic.com | info@hologic.com | +1.781.999.7300

MED-00251 Rev.002 (06/17) © 2017 Hologic, Inc. All rights reserved. Printed in USA. Specifications are subject to change without prior notice. Hologic is a trademarks and/or registered trademarks of Hologic and/or Hologic subsidiaries in the United States and/ or other countries. All other trademarks and registered trademarks are the property of their respective owners. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic representative or write to womenshealth@hologic.com.